NASDAQ:ONCE - Spark Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $46.11 -1.65 (-3.45 %) (As of 10/22/2018 11:55 AM ET)Previous Close$47.76Today's Range$45.28 - $47.9052-Week Range$41.06 - $96.59Volume5,187 shsAverage Volume502,625 shsMarket Capitalization$1.79 billionP/E Ratio-6.04Dividend YieldN/ABeta2.24 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A. In addition, its product candidates and development programs include SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of CLN2 disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and other neurodegenerative diseases. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania. Receive ONCE News and Ratings via Email Sign-up to receive the latest news and ratings for ONCE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNASDAQ:ONCE CUSIPN/A Webwww.sparktx.com Phone888-772-7560 Debt Debt-to-Equity RatioN/A Current Ratio18.48 Quick Ratio18.14 Price-To-Earnings Trailing P/E Ratio-6.04 Forward P/E Ratio-32.02 P/E GrowthN/A Sales & Book Value Annual Sales$12.07 million Price / Sales143.53 Cash FlowN/A Price / CashN/A Book Value$13.88 per share Price / Book3.32 Profitability EPS (Most Recent Fiscal Year)($7.63) Net Income$-253,480,000.00 Net Margins-185.46% Return on Equity-17.33% Return on Assets-13.83% Miscellaneous Employees315 Outstanding Shares37,570,000Market Cap$1.79 billion Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions What is Spark Therapeutics' stock symbol? Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE." How were Spark Therapeutics' earnings last quarter? Spark Therapeutics Inc (NASDAQ:ONCE) released its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.34. The biotechnology company earned $25.19 million during the quarter, compared to the consensus estimate of $29.44 million. Spark Therapeutics had a negative net margin of 185.46% and a negative return on equity of 17.33%. View Spark Therapeutics' Earnings History. When is Spark Therapeutics' next earnings date? Spark Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 6th 2018. View Earnings Estimates for Spark Therapeutics. What price target have analysts set for ONCE? 21 brokers have issued 12 month target prices for Spark Therapeutics' shares. Their forecasts range from $40.00 to $103.00. On average, they anticipate Spark Therapeutics' share price to reach $70.90 in the next twelve months. This suggests a possible upside of 52.8% from the stock's current price. View Analyst Price Targets for Spark Therapeutics. What is the consensus analysts' recommendation for Spark Therapeutics? 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spark Therapeutics in the last year. There are currently 2 sell ratings, 8 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Spark Therapeutics. What are Wall Street analysts saying about Spark Therapeutics stock? Here are some recent quotes from research analysts about Spark Therapeutics stock: 1. According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (10/13/2018) 2. Raymond James analysts commented, "We are maintaining our Outperform rating for shares of ONCE. This morning the E.U.’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of LUXTURNA for the treatment of vision loss due to inherited retinal dystrophy (IRD) caused by mutations in the retinal pigment epithelium- specific 65 kDa (RPE65) gene. Along with robust data from the company’s Phase III study that demonstrated safety, efficacy, and durability of response for up to three years, the company awaits a marketing authorization from the European Commission within two months to become the first gene therapy for a genetic disease approved in both the U.S. and E.U. With U.S." (9/21/2018) 3. Mizuho analysts commented, "We further think it is pre-mature to draw the conclusion that SPK-8011 is inferior to the competing product from BioMarin (BMRN, non-rated). We reduce our PT from $91 to $77 after removing the M&A premium of our valuation per revised valuation methodology and we maintain our revenue forecasts." (8/8/2018) 4. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and 12-month PT of $103 on 2Q18 financial results and program updates. During the call, Spark announced additional updates from the Phase 1/2 trial of SPK-8011 in hemophilia A. While the occurrence of two immune responses leading to inadequate FVIII activity level add challenges for the program, we believe the company is well equipped to address them as the program moves to late-stage development." (8/7/2018) Who are some of Spark Therapeutics' key competitors? Some companies that are related to Spark Therapeutics include BIO-TECHNE (TECH), bluebird bio (BLUE), Ablynx (ABLYF), Aerie Pharmaceuticals (AERI), argenx (ARGX), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), China Biologic Products (CBPO), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Denali Therapeutics (DNLI), Sangamo Therapeutics (SGMO) and Rubius Therapeutics (RUBY). Who are Spark Therapeutics' key executives? Spark Therapeutics' management team includes the folowing people: Mr. Jeffrey D. Marrazzo, Co-Founder, CEO & Director (Age 39)Dr. Katherine A. High, Co-Founder, Pres, Head of R&D and Director (Age 66)Mr. Stephen W. Webster, Chief Financial Officer (Age 57)Mr. Joseph W. La Barge Esq., J.D., Chief Legal Officer & Sec. (Age 47)Mr. Daniel R. Faga, Chief Bus. Officer (Age 38) When did Spark Therapeutics IPO? (ONCE) raised $88 million in an IPO on Friday, January 30th 2015. The company issued 5,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers. Who are Spark Therapeutics' major shareholders? Spark Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Asset Management Company LTD (0.07%), NJ State Employees Deferred Compensation Plan (0.02%) and Bank of Montreal Can (0.01%). Company insiders that own Spark Therapeutics stock include Anand Mehra, Barge Joseph La, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, John Furey, Katherine A High and Stephen W Webster. View Institutional Ownership Trends for Spark Therapeutics. Which major investors are buying Spark Therapeutics stock? ONCE stock was purchased by a variety of institutional investors in the last quarter, including NJ State Employees Deferred Compensation Plan, Bank of Montreal Can and Sumitomo Mitsui Asset Management Company LTD. View Insider Buying and Selling for Spark Therapeutics. How do I buy shares of Spark Therapeutics? Shares of ONCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Spark Therapeutics' stock price today? One share of ONCE stock can currently be purchased for approximately $46.40. How big of a company is Spark Therapeutics? Spark Therapeutics has a market capitalization of $1.79 billion and generates $12.07 million in revenue each year. The biotechnology company earns $-253,480,000.00 in net income (profit) each year or ($7.63) on an earnings per share basis. Spark Therapeutics employs 315 workers across the globe. What is Spark Therapeutics' official website? The official website for Spark Therapeutics is http://www.sparktx.com. How can I contact Spark Therapeutics? Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected] MarketBeat Community Rating for Spark Therapeutics (NASDAQ ONCE)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 423 (Vote Outperform)Underperform Votes: 327 (Vote Underperform)Total Votes: 750MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe ONCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/22/2018 by MarketBeat.com StaffFeatured Article: Stock Selection - What is cash flow?